Despite advances in immunotherapy, a large fraction of cancer patients fails to respond. Immune mechanisms behind this resistance are poorly elucidated. The objective of our research program is to comprehensively characterize and study the role of a new class of white blood cells, called resident memory T cells (TRM), in antitumor immunity and response to cancer immunotherapy.

Non-conventionnals Epitopes cancer immune responses

back to job offer list

back to clinical trials

Non-conventionnals epitopes cancer immune responses

This group belongs to the UMR 1015 "Tumour Immunology and anti-cancer immunotherapy".

Oncogenesis and tumour progression of melanoma

back to job offer list

back to clinical trials

Oncogenesis and tumour progression of melanoma group

This team belongs to the UMR 1279 - Tumor cell dynamics

In our group we are studying in parrallel:

The biology of melanocytes which are pigment producing cells responsible for skin color
The biology of cutaneous melanoma, which derives fromm melanocytes.

Using a comprehensive approach, we strive to identify mutations responsible for melanoma transformation and genes involved in metastasis.

Tumour immunology and immunotherapy - Current research

back to job offer list

back to clinical trials

Tumour immunology and immunotherapy

Group 1 of the Inserm (National Institute of Health and Medical Research) UMR 1015 research unit, « Tumour immunology and immunotherapy of cancer », is under the direction of Professor Laurence Zitvogel. Between 2015 and 2018 it will be exploring three lines of research:
- Gut microbiota and pro- or anti-tumour inflammatory/immunological activity, by measuring the effect of specific therapies on their regulation,